DiscoverWTR Small-Cap SpotlightVivos Therapeutics Chairman and CEO Kirk Huntsman Discusses Recent FDA Clearance in Pediatric OSA
Vivos Therapeutics Chairman and CEO Kirk Huntsman Discusses Recent FDA Clearance in Pediatric OSA

Vivos Therapeutics Chairman and CEO Kirk Huntsman Discusses Recent FDA Clearance in Pediatric OSA

Update: 2024-09-25
Share

Description

Send us a text

Kirk Huntsman, Chairman and CEO of Vivos Therapeutics joins us on this week’s WTR Small-Cap Spotlight following the company announcement of its first known FDA clearance for a medical device in pediatric obstructive sleep apnea. He discusses what the FDA approval means for the millions of US children with this serious health condition. Kirk talks about how the pediatric market fits into Vivos’ new marketing and distribution strategy, as well as the progress with medical-based affiliations.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Vivos Therapeutics Chairman and CEO Kirk Huntsman Discusses Recent FDA Clearance in Pediatric OSA

Vivos Therapeutics Chairman and CEO Kirk Huntsman Discusses Recent FDA Clearance in Pediatric OSA

Water Tower Research